[The thrombocyte function of subjects with atherogenic hyperlipidemias during lovastatin treatment].
The effects of lovastatin on in vivo spontaneous and in vitro ADP-induced platelet aggregability were studied in the blood of 36 persons with primary hyperlipidemias (HLP) of Types IIIa and IIb. In addition to decreases in blood cholesterol levels by an average of 33% and the atherogenicity coefficient to the normal levels, there was an increase in spontaneous and/or ADP-induced platelet aggregability in the first 2-3 months of lovastatin therapy. Lovastatin-induced in anti- and proaggregatory potential in the platelet-vascular wall system towards of the latter and spontaneous intravascular platelet formation suggest that there is a higher risk for thromboembolic events in the examined patients with Type II HLP, especially if they have coronary heart disease, during early stages of the drug administration. Therefore, there are reasons for recommending that lovastatin should be given under the control of the platelet hemostatic system.